Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Goldman Sachs Sticks to Their Sell Rating for Novartis AG (NOVN)

Tipranks - Tipranks - Sat Mar 21, 5:58AM CDT

Goldman Sachs analyst James Quigley maintained a Sell rating on Novartis AG today and set a price target of CHF101.00.

Claim 70% Off TipRanks Premium

According to TipRanks, Quigley is an analyst with an average return of -10.4% and a 33.75% success rate. Quigley covers the Healthcare sector, focusing on stocks such as Merck KGaA, Novo Nordisk, and Sartorius.

In addition to Goldman Sachs, Novartis AG also received a Sell from HSBC’s Rajesh Kumar in a report issued on March 17. However, on March 6, Berenberg Bank assigned a Hold rating to Novartis AG (Six Swiss: NOVN).

See the top stocks recommended by analysts >>

Based on Novartis AG’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of CHF13.44 billion and a net profit of CHF2.43 billion. In comparison, last year the company earned a revenue of CHF13.56 billion and had a net profit of CHF2.82 billion

Read More on CH:NOVN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).